Aug 5 (Reuters) - U.S. drugmaker Pfizer PFE.N raised its full-year profit forecast on Tuesday, boosted by robust demand for its heart disease drug, Vyndaqel, and some older treatments.
The drugmaker now expects to earn $2.90 to $3.10 per share on an adjusted basis in 2025, compared with its previous expectations of $2.80 to $3.00 per share.